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The gut mucosa is the major site of contact with antigens.
It holds the largest mass of lymphoid tissue in the body.
Under physiological conditions, microbiota and dietary
antigens are the natural sources of stimulation for the gut-
associated lymphoid tissue (GALT) and for the immune
system as a whole. Most GALT cells are activated, and a
variety of proinﬂammatory mediators are found in this site.
Regulatory elements, however, counterbalance local inﬂam-
matory events in such a way that a delicate yet robust
balance keeps the gut homeostasis in check. Normal anti-
genic contact through the gut mucosa induces two major
noninﬂammatory immune responses, oral tolerance, and
production of secretory IgA. However, under pathological
circumstances mucosal homeostasis is disturbed resulting
in inﬂammatory conditions such as food hypersensitivity
and inﬂammatory bowel diseases (IBDs). The number of
reported cases of food allergy in children grew 18% in
the past decade [1]. At the same time, the incidence and
prevalence of chronic inﬂammatory bowel diseases such as
ulcerative colitis and Crohn’s disease is increasing yearly
in US, Europe, Asia, and Latin America [2]. Although
therapies for these diseases have improved, they have many
side eﬀects and are still only modestly successful for long-
term management. The growing incidence of both types of
conditionsandtheneedfortherapeuticalternativesdemands
from the scientiﬁc community a better understanding of
the mechanisms involved in intestinal homeostasis and the
pathological settings that may trigger gut inﬂammation.
Theaimofthisspecialissueistoshedsomelightonthese
mechanisms as well as to address alternative therapeutic
and preventive approaches for gut inﬂammatory diseases. It
comprises ﬁve review articles and ten research articles.
The opening review article by Ramos is a critical ap-
praisal of inﬂammation as a physiological phenomenon
related to the development of multicellular organisms rather
than solely a pathological event associated with disease and
anti-infectious defense mechanisms. Since the great majority
of processes in the gut are a consequence of chronic exposure
to large amounts of harmless and often beneﬁcial antigens,
the authorsdiscuss how the immune systemassimilates these
perturbations without generating tissue damage. A. P. da
CunhaandH.L.Weinerreviewthestudiesonthetolerogenic
eﬀectsoforallyadministeredanti-CD3monoclonalantibody
in experimental models of autoimmune diseases. Anti-CD3
antibody is biologically active in the gut and may represent
a powerful immunologic approach that would be applicable
for the treatment of human autoimmune conditions. P.
Moingeon and L. Mascarell present a review on the oral
lymphoid tissue that comprises various antigen-presenting
cells (APCs), resident CD4+ T cells but few mast cells and
eosinophils. Interestingly, in the absence of danger signals,
the APCs at this site are mostly tolerogenic. These features
endow the oral mucosa with properties of a site for immune
intervention. Indeed, sublingual vaccines using recombinant
allergens are being developed as a novel immunomodulatory
strategy to control allergic diseases. The paper by C. T.2 Clinical and Developmental Immunology
Murphy and coworkers reviews the role of leukocyte traf-
ﬁcking to the intestinal mucosa in the pathogenesis of
inﬂammatory bowel diseases (IBDs) and the various strate-
gies employed to target leukocyte migration as a putative
therapeutic tool to control these disorders.
In line with these reviewed topics, the original papers in
this issue address several aspects of oral tolerance induction,
gut inﬂammatory diseases, and intestinal infection. Two
papers present data on the mechanisms involved in oral
tolerancetoinﬂammatoryreactionsoccurringinthelung.G.
M. Azevedo, Jr., and coworkers showed that intraperitoneal
injection of ovalbumin (OVA) in adjuvant minutes before
intravenous injection of Schistosoma mansoni eggs into OVA
tolerant mice blocked the increase of pulmonary granulo-
mas. This indirect eﬀe c to fo r a lt o l e r a n c et oO V Ac o r r e l a t e s
with a reduction in the recruitment of inﬂammatory cells
to the lung suggesting that this is one of the mechanisms
by which oral tolerance mediates its indirect eﬀects towards
other context-related antigens. The role of regulatory T cells
was studied by L. Faustino and coworkers using a model
of lung eosinophilic inﬂammation. Interestingly, at the peak
of airway inﬂammation, the number of regulatory T cells
was much higher in allergic mice than in tolerant mice.
These regulatory T cells likely play a role in controlling
disease progression in allergic mice. The earlier appearance
of regulatory T cells in tolerant mice may be the critical
parameter that prevents airway inﬂammation instead of
merely limiting it.
Studying regulatory mechanisms induced by oral tol-
erance, M. Ruberti and coworkers compared eﬀects in the
intestinal mucosa of OVA feeding to BALB/c versus OVA
TCR transgenic (DO11.10) mice. OVA-fed BALB/c mice had
reduced levels of cytokines in the intestinal mucosa, whereas
frequencies of intraepithelial lymphocytes (IELs) expressing
Foxp3 and CD103 increased. On the other hand, in OVA-
fed DO11.10 mice the intestinal mucosa showed signs of
inﬂammation with increased local cytokine production, and
reduction in IEL numbers. Having demonstrated previously
that DO11.10 mice could not be rendered tolerant to OVA
by the oral route, the authors suggest that the altered
proportions of mucosal inﬂammatory/regulatory T cells and
IELs in these mice are related to resistance to oral tolerance
induction.
Two other papers deal with the controversial practice of
delaying the introduction of allergenic foods into the infant
diet to prevent food allergy development. Contrary to this
wide-spread believe, both studies showed that early antigen
exposure by breast feeding is able to prevent sensitization in
allergy-prone BN rat pups (A. El-Merhibi and coworkers)
and in the oﬀspring of allergy-susceptible BALB/c mice
(T. Yamamoto and coworkers). Inhibition of speciﬁc IgE
production and food allergy by oral tolerance to the breast-
fed antigen was followed by increases in regulatory T cells
and anti-inﬂammatory cytokines.
The other reports studied two immunomodulatory
strategies for food allergy: a dietary component and a
probiotic. O. G. de Matos and coworkers investigated the
eﬀect of dietary supplementation with n-3 polyunsaturated
fatty acids (PUFA, ﬁsh oil source) in an experimental model
of food allergy using BALB/c mice. Treatment with n-3
PUFA reduced all inﬂammatory parameters associated with
food allergy including serum levels of antiovalbumin IgE
and IgG1, as well as leukocyte recruitment, mucus produc-
tion, and Paneth cell degranulation in the small intestine.
Likewise, administration of Lactococcus lactis NCC 2287 to
BALB/c mice, once sensitized but not before sensitization,
reduced allergic manifestations upon allergen challenge.
According to A. W. Zuercher and coworkers, the beneﬁcial
eﬀect of this strain of L. lactis correlates with localized
inhibition of Th2 cytokines, particularly IL-13. Therefore,
these two strategies characterize promising alternative agents
for either prevention or treatment of food allergy.
In addition to hypersensitivity reactions to food, dys-
regulated gut immune responses are also observed in IBD.
Two other papers address the role of IL-10 and autophagia
in IBD development. A. C. Gomes-Santos and coworkers
report a kinetic study on the changes in cytokines and
lymphoid cells in the intestinal mucosa during the course
of spontaneous colitis in IL-10-deﬁcient 129 Sv/Ev mice.
Although histological signs of colitis only start at 10 weeks
of age reaching overt gut inﬂammation at 16 weeks of age,
decrease in the frequency of CD4+CD25+Foxp3+ regulatory
T cells and increase in activated T cells and in IL-17 at
the gut mucosa can be detected as early as 6 weeks of age.
Interestingly, oral tolerance can be induced in diseased 16-
week-old mice by a continuous feeding protocol indicating
that this could be an alternative therapeutic strategy for
established colitis. Autophagy is another process reported
to be involved in intestinal immune homeostasis due to its
participation in the digestion of intracellular pathogens and
in antigen presentation. To investigate the role of autophagy
in the development of experimental models of IBD, N.
Wittkopf and coworkers generated mice with intestinal
epithelial deletion of the autophagy gene Atg7. Knockout
mice showed reduced size of granules and decreased levels
of lysozyme in Paneth cells. However, this had no eﬀect on
susceptibility in mouse models of experimentally induced
colitis leaving this association as an open question for future
studies.
A. Kantele investigated gut immune responses to per-
sistent intestinal infection by monitoring gut-originating
plasmablasts in blood. Even in symptomless patients with
Salmonella, Yersinia, or Campylobacter gastroenteritis and in
volunteers receiving an oral typhoid vaccine, these persisting
pathogens/antigens keep seeding plasmablasts into the cir-
culation. Assaying these cells might provide a less invasive
tool for research on intestinal immune responses in diseases
in which persisting microbes have a potential pathogenetic
signiﬁcance.
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